Simbrinza

Simbrinza

Manufacturer:

Novartis

Distributor:

DKSH
Concise Prescribing Info
Contents
Per mL Brinzolamide 10 mg, brimonidine tartrate 2 mg
Indications/Uses
Decrease of elevated IOP in adults w/ open-angle glaucoma or ocular HTN for whom monotherapy provides insufficient IOP reduction.
Dosage/Direction for Use
Adult including elderly 1 drop in affected eye bd. 
Contraindications
Hypersensitivity to brinzolamide, brimonidine or sulphonamides. Hyperchloraemic acidosis. Concomitant MAOI therapy, antidepressants affecting noradrenergic transmission eg, TCAs, mianserin. Severe renal impairment. Neonates & infants <2 yr.
Special Precautions
Discontinue use if signs of serious reactions or hypersensitivity occur. Not recommended in narrow-angle glaucoma. Patients w/ compromised corneas eg, w/ DM or corneal dystrophies; low endothelial cell count; severe or unstable & uncontrolled CV disease; depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans. May cause eye irritation due to benzalkonium Cl. Remove contact lens prior to application & wait 15 min before reinsertion. Prolonged use. Concomitant use w/ antihypertensives &/or cardiac glycosides. May affect ability to drive & use machines. Hepatic & severe renal impairment. Women of childbearing potential should use effective contraception. Not recommended during pregnancy. Not to be used during lactation. Not recommended in childn & adolescents ≥2 yr.
Adverse Reactions
Somnolence, dizziness, dysgeusia; eye allergy & pain, keratitis, ocular discomfort & hyperaemia, blurred & abnormal vision, conjunctival blanching; dry mouth.
Drug Interactions
Blunted ocular hypotensive response by TCAs. Additive or potentiated effect w/ CNS depressants. Reduced pulse & BP w/ α-adrenergic agonists. Additive systemic effects w/ oral carbonic anhydrase inhibitors. Inhibited metabolism w/ CYP3A4 inhibitors. Medicinal products affecting metabolism & uptake of circulating amines eg, chlorpromazine, methylphenidate, reserpine, serotonin-norepinephrine reuptake inhibitors. Concomitant use w/ antihypertensives &/or cardiac glycosides; isoprenaline, prazosin.
MIMS Class
Antiglaucoma Preparations
ATC Classification
S01EC54 - brinzolamide, combinations ; Belongs to the class of carbonic anhydrase inhibitors. Used in the treatment of glaucoma.
Presentation/Packing
Form
Simbrinza eye susp
Packing/Price
5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in